Kamada Ltd. (NASDAQ:KMDA) was the recipient of a large decline in short interest in the month of November. As of November 15th, there was short interest totalling 6,800 shares, a decline of 22.7% from the October 31st total of 8,800 shares. Currently, 0.0% of the company’s shares are short sold. Based on an average daily volume of 21,800 shares, the short-interest ratio is presently 0.3 days.
A number of institutional investors have recently modified their holdings of KMDA. JPMorgan Chase & Co. acquired a new position in Kamada during the 2nd quarter valued at approximately $26,000. C M Bidwell & Associates Ltd. acquired a new stake in shares of Kamada in the second quarter worth $48,000. Eagle Ridge Investment Management acquired a new stake in shares of Kamada in the third quarter worth $171,000. Engine Capital Management LP acquired a new stake in shares of Kamada in the second quarter worth $195,000. Finally, BlackRock Inc. acquired a new stake in shares of Kamada in the second quarter worth $216,000. Institutional investors and hedge funds own 15.48% of the company’s stock.
A number of equities analysts recently commented on KMDA shares. HC Wainwright reaffirmed a “buy” rating and set a $11.00 price target on shares of Kamada in a research note on Wednesday, August 7th. ValuEngine raised shares of Kamada from a “sell” rating to a “hold” rating in a research note on Monday, November 11th. Finally, Zacks Investment Research cut shares of Kamada from a “hold” rating to a “sell” rating in a research report on Tuesday, August 13th.
Kamada (NASDAQ:KMDA) last posted its quarterly earnings data on Wednesday, November 13th. The biotechnology company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.09 by $0.05. Kamada had a net margin of 24.16% and a return on equity of 28.62%. The firm had revenue of $33.07 million during the quarter, compared to analyst estimates of $28.94 million. As a group, equities research analysts anticipate that Kamada will post 0.55 EPS for the current year.
Kamada Company Profile
Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates through two segments, Proprietary Products and Distribution. The company offers respiratory products, including Glassia for use in augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin (AAT) deficiency.
Featured Story: What is a stock portfolio tracker?
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.